OSA
MCID: APN008
MIFTS: 65

Apnea, Obstructive Sleep (OSA)

Categories: Blood diseases, Mental diseases, Respiratory diseases

Aliases & Classifications for Apnea, Obstructive Sleep

MalaCards integrated aliases for Apnea, Obstructive Sleep:

Name: Apnea, Obstructive Sleep 56
Obstructive Sleep Apnea Syndrome 56 12 25 29 6 15
Obstructive Sleep Apnea 12 74 25 15 62 17
Sleep Apnea, Obstructive 25 43 71
Upper Airway Resistance Sleep Apnea Syndrome 25 71
Sleep Apnea/hypopnea Syndrome 56 25
Osas 56 25
Sahs 56 25
Osa 56 25
Sleep Apnea/hypopnea Syndrome; Sahs; Osahs 56
Obstructive Sleep Apnea Syndrome; Osas 56
Sleep Apnea Syndrome, Obstructive 25
Sleep Apnea Hypopnea Syndrome 25
Sleep Apnea Obstructive 54
Sleep Apnea Syndromes 71
Apnea, Obstructive 25
Obstructive Apnea 25
Osahs 25

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
apnea, obstructive sleep:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0050848
OMIM 56 107650
ICD9CM 34 327.23
MeSH 43 D020181
SNOMED-CT 67 78275009
ICD10 32 G47.33
MedGen 41 C0520679
UMLS 71 C0037315 C0520679 C0751761

Summaries for Apnea, Obstructive Sleep

Genetics Home Reference : 25 Obstructive sleep apnea is a condition in which individuals experience pauses in breathing (apnea) during sleep, which are associated with partial or complete closure of the throat (pper airway). Complete closure can lead to apnea while partial closure allows breathing but decrease the intake of oxygen (hypopnea). Individuals with obstructive sleep apnea may experience interrupted sleep with frequent awakenings and loud snoring. Repeated pauses in breathing lead to episodes of lower-than-normal oxygen levels (hypoxemia) and a buildup of carbon dioxide (hypercapnia) in the bloodstream. Interrupted and poor quality sleep can lead to daytime sleepiness and fatigue, impaired attention and memory, headaches, depression, and sexual dysfunction. Daytime sleepiness leads to a higher risk of motor vehicle accidents in individuals with obstructive sleep apnea. Obstructive sleep apnea is also associated with an increased risk of developing insulin resistance, which is an inability to regulate blood sugar levels effectively; high blood pressure (hypertension); heart disease; and stroke.

MalaCards based summary : Apnea, Obstructive Sleep, also known as obstructive sleep apnea syndrome, is related to hypercholesterolemia, familial, 1 and acromegaly, and has symptoms including seizures, tremor and dyspnea. An important gene associated with Apnea, Obstructive Sleep is LEP (Leptin), and among its related pathways/superpathways are p70S6K Signaling and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Montelukast and Dexlansoprazole have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are focal impaired awareness seizure and anosmia

Disease Ontology : 12 A sleep apnea that is characterized by repeated collapse and obstruction of the upper airway during sleep, which results in reduced airflow (hypopnea) or complete airflow cessation (apnea), oxygen desaturation, and arousals from sleep.

OMIM : 56 Obstructive sleep apnea is a common, chronic, complex disease associated with serious cardiovascular and neuropsychologic sequelae and with substantial social and economic costs (Palmer et al., 2003). (107650)

PubMed Health : 62 About obstructive sleep apnea: We all know what it is like to feel tired after a sleepless night because of things like noise, worries or stress. But what if you do actually get enough sleep and still feel absolutely beat the next morning? This is normal for many people with obstructive sleep apnea (OSA): They do not get enough air while they are sleeping (but do not usually notice this), have breathing pauses, and feel very sleepy during the day. In the long term, this increases their risk of developing other illnesses and can have a huge effect on their quality of life.

Wikipedia : 74 Obstructive sleep apnea (OSA) is the most common type of sleep apnea and is characterised by repeated... more...

Related Diseases for Apnea, Obstructive Sleep

Diseases related to Apnea, Obstructive Sleep via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1114)
# Related Disease Score Top Affiliating Genes
1 hypercholesterolemia, familial, 1 31.3 NOS3 INS CRP ACE
2 acromegaly 31.3 LEP INS IGF1 GHRL ADIPOQ
3 barrett esophagus 31.2 LEP IL6 GHRL ADIPOQ
4 tricuspid valve insufficiency 31.2 EDN1 CRP ACE
5 interstitial lung disease 31.2 TNF IL6 EDN1 CRP
6 fatty liver disease, nonalcoholic 1 31.2 LEP INS ADIPOQ
7 aortic disease 31.2 REN IL6 CRP ACE
8 microvascular complications of diabetes 3 31.1 REN INS ACE
9 mitral valve insufficiency 31.1 REN CRP ACE
10 ankylosis 31.1 TNF EDN1 CRP
11 sickle cell anemia 31.1 TNF NOS3 IL6 EDN1
12 diabetic autonomic neuropathy 31.1 REN INS ACE
13 pulmonary disease, chronic obstructive 31.1 TNF INS IL6 CRP ACE
14 obesity-hypoventilation syndrome 31.1 LEP IL6 ADIPOQ
15 aortic aneurysm, familial abdominal, 1 31.0 IL6 CRP ACE
16 irritable bowel syndrome 31.0 TNF IL6 HTR2A GHRL
17 vascular dementia 31.0 TNF IL6 IGF1 CRP ACE
18 angina pectoris 31.0 NOS3 INS IL6 EDN1 CRP ACE
19 hypopituitarism 31.0 LEP INS IGF1 CRP
20 duodenal ulcer 31.0 TNF INS IL6
21 diabetic neuropathy 31.0 REN LEP INS ACE
22 lipid metabolism disorder 30.9 LEP INS IL6 CRP ADIPOQ ACE
23 diabetic macular edema 30.9 REN NOS3 IL6
24 muscle hypertrophy 30.9 LEP IGF1 EDN1 AGT
25 familial partial lipodystrophy 30.9 TNF LEP INS ADIPOQ
26 non-alcoholic steatohepatitis 30.9 TNF INS IL6 ADIPOQ
27 liver disease 30.9 TNF LEP INS IL6 ADIPOQ
28 macular retinal edema 30.9 TNF INS IL6 ACE
29 eating disorder 30.9 LEP HTR2A HCRT GHRL ADIPOQ
30 amyloidosis 30.9 TNF INS IL6 CRP
31 atypical depressive disorder 30.9 LEP HTR2A CRP
32 carotid artery disease 30.9 REN CRP ACE
33 idiopathic edema 30.9 INS EDN1 ADIPOQ ACE
34 pericardial effusion 30.9 REN IL6 CRP ACE
35 normal pressure hydrocephalus 30.9 IGF1 HCRT ACE
36 fatty liver disease 30.9 TNF LEP INS IL6 CRP ADIPOQ
37 non-alcoholic fatty liver disease 30.9 TNF LEP INS IL6 CRP ADIPOQ
38 amenorrhea 30.8 LEP INS IGF1 GHRL
39 viral hepatitis 30.8 TNF INS IL6 CRP
40 thyroiditis 30.8 TNF INS IL6
41 cardiogenic shock 30.8 IL6 CRP
42 lipodystrophy, familial partial, type 2 30.8 LEP INS ADIPOQ
43 insulin-like growth factor i 30.8 LEP INS IGF1
44 bronchiolitis 30.8 TNF IL6 CRP
45 laryngitis 30.8 TNF IL6 CRP
46 narcolepsy 30.8 TNF LEP IL6 HTR2A HCRT GHRL
47 nonarteritic anterior ischemic optic neuropathy 30.8 NOS3 EDN1 CRP AGT ACE
48 arthropathy 30.8 TNF IL6 IGF1 CRP
49 chronic thromboembolic pulmonary hypertension 30.8 EDN1 CRP
50 motor neuron disease 30.8 TNF INS IL6 IGF1 HTR2A

Graphical network of the top 20 diseases related to Apnea, Obstructive Sleep:



Diseases related to Apnea, Obstructive Sleep

Symptoms & Phenotypes for Apnea, Obstructive Sleep

Human phenotypes related to Apnea, Obstructive Sleep:

31
# Description HPO Frequency HPO Source Accession
1 focal impaired awareness seizure 31 HP:0002384
2 anosmia 31 HP:0000458
3 obstructive sleep apnea 31 HP:0002870
4 excessive daytime somnolence 31 HP:0001262
5 snoring 31 HP:0025267

Symptoms via clinical synopsis from OMIM:

56
Neuro:
anosmia
partial complex seizures

Misc:
hypersomnolence
restless movements during sleep

Resp:
obstructive sleep apnea
snoring

Clinical features from OMIM:

107650

UMLS symptoms related to Apnea, Obstructive Sleep:


seizures, tremor, dyspnea, back pain, apnea, pain, headache, syncope, excessive daytime somnolence, wheezing, snoring, chronic pain, sciatica, sleep disturbances, cheyne-stokes respiration, coughing, vertigo/dizziness, sleeplessness, labored breathing, insomnia with sleep apnea, unspecified, hypersomnia with sleep apnea, unspecified, disruption of 24 hour sleep wake cycle, unspecified

MGI Mouse Phenotypes related to Apnea, Obstructive Sleep:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.32 ACE ADIPOQ AGT CRP EDN1 FXYD1
2 behavior/neurological MP:0005386 10.31 ACE ADIPOQ AGT AHI1 GHRL HCRT
3 homeostasis/metabolism MP:0005376 10.24 ACE ADIPOQ AGT AHI1 CRP EDN1
4 growth/size/body region MP:0005378 10.22 ACE ADIPOQ AGT AHI1 EDN1 HCRT
5 adipose tissue MP:0005375 10.21 ACE ADIPOQ AGT GHRL IGF1 IL6
6 endocrine/exocrine gland MP:0005379 10.17 ACE ADIPOQ EDN1 GHRL HTR2A IGF1
7 immune system MP:0005387 10.1 ACE ADIPOQ AGT AHI1 CRP IGF1
8 digestive/alimentary MP:0005381 10.06 EDN1 GHRL HTR2A IL6 INS LEP
9 muscle MP:0005369 9.97 ADIPOQ AGT EDN1 FXYD1 HCRT HTR2A
10 liver/biliary system MP:0005370 9.86 ACE ADIPOQ AGT IL6 INS LEP
11 nervous system MP:0003631 9.73 ADIPOQ AGT AHI1 EDN1 HCRT IGF1
12 renal/urinary system MP:0005367 9.36 ACE ADIPOQ AGT AHI1 EDN1 IGF1

Drugs & Therapeutics for Apnea, Obstructive Sleep

PubMed Health treatment related to Apnea, Obstructive Sleep: 62

If you are very overweight , losing weight can help improve sleep apnea . There are also many treatment options that aim to relieve sleep apnea. These include machines that support breathing during the night, surgery , and special aids such as mouth guards. Some of these treatments have been scientifically proven to help people with sleep apnea. Medication is currently not used for the treatment of sleep apnea. There is no scientific evidence that the available medications work. The most effective treatment for severe sleep apnea is called CPAP therapy . CPAP stands for “continuous positive airway pressure.” In this treatment approach, air is taken from the immediate surroundings and blown into your airways at night using low pressure. While you sleep, you wear a breathing mask that is connected to a machine called a respirator. The pressure keeps the upper airways open. People who use this machine have fewer breathing pauses, or even none at all. This can noticeably improve the symptoms such as tiredness during the day. Common side effects include a dry throat and an irritated, sometimes blocked nose .

Drugs for Apnea, Obstructive Sleep (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 445)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
3
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
4
Zopiclone Approved Phase 4 43200-80-2 5735
5
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
6
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
7
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
8
Sodium oxybate Approved Phase 4 502-85-2 5360545
9
Budesonide Approved Phase 4 51333-22-3 63006 5281004
10
Sodium citrate Approved, Investigational Phase 4 68-04-2
11
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
12
Desflurane Approved Phase 4 57041-67-5 42113
13
Donepezil Approved Phase 4 120014-06-4 3152
14
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
15
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
16
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
17
Adalimumab Approved Phase 4 331731-18-1 16219006
18
Pantoprazole Approved Phase 4 102625-70-7 4679
19
Eplerenone Approved Phase 4 107724-20-9 150310 443872
20
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
21
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
22
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
23
Pseudoephedrine Approved Phase 4 90-82-4 7028
24
Ephedrine Approved Phase 4 299-42-3 9294
25
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
26
Liraglutide Approved Phase 4 204656-20-2 44147092
27
Levodopa Approved Phase 4 59-92-7 6047
28
Carbidopa Approved Phase 4 28860-95-9 34359
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
30
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
31
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
32
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
33
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
34
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
35
Finasteride Approved Phase 4 98319-26-7 57363
36
Metformin Approved Phase 4 657-24-9 14219 4091
37
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
38
Hydroxychloroquine Approved Phase 4 118-42-3 3652
39
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
40
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
41
Norepinephrine Approved Phase 4 51-41-2 439260
42
Losartan Approved Phase 4 114798-26-4 3961
43
Opium Approved, Illicit Phase 4 8008-60-4
44
Loperamide Approved Phase 4 53179-11-6 3955
45
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
46
Zolpidem Approved Phase 4 82626-48-0 5732
47
Promethazine Approved, Investigational Phase 4 60-87-7 4927
48
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
49
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
50
tannic acid Approved Phase 4 1401-55-4

Interventional clinical trials:

(show top 50) (show all 2060)
# Name Status NCT ID Phase Drugs
1 Open, Prospective Study for the Validation of the Predictive Value of Upper Airway Segmentation and CFD Analysis on Outcome Parameters of the Mandibular Replacement Appliance (MRA) Therapy in Obstructive Sleep Apnea Hypopnea Syndrome OSAHS) Patients Unknown status NCT01524510 Phase 4
2 Comparison of the Pentax AWS® With the Macintosh Laryngoscope for Tracheal Intubation in Patients With Obstructive Sleep Apnea Syndrome: a Randomized Comparative Study Unknown status NCT01428570 Phase 4
3 PROMAD : Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Unknown status NCT01532050 Phase 4
4 Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study Unknown status NCT00912457 Phase 4 donepezil;placebo
5 Cost-utility Study of CPAP Treatment in Obstructive Sleep Apnea Patients Unknown status NCT01590420 Phase 4
6 Effects of Continuous Positive Airway Pressure (CPAP) and Nebivolol Treatment on Arterial Blood Pressure and Endothelial Function in Hypertensive OSA Patients. Unknown status NCT01771406 Phase 4 Nebivolol
7 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
8 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated Heart Failure Patients With Obstructive Sleep Apnea: A Two Center Pilot Study Unknown status NCT02963597 Phase 4
9 A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA Unknown status NCT02724865 Phase 4
10 A Placebo Controlled Double Blinded Crossover Study of the Antihypertensive Efficacy of Guanfacine vs Hydrochlorothiazide in Obstructive Sleep Apnea (OSA) Associated Hypertension Unknown status NCT02699125 Phase 4 Guanfacine;Hydrochlorothiazide
11 A Randomized, Double-blind, Placebo-controlled Study of Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
12 Blood Pressure Reduction Induced by Continuous Positive Airway Pressure (CPAP) in Sleep Apnea Patients at High Cardiovascular Risk : A Randomized Controlled Trial Comparing Usual CPAP Care Versus a Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform Unknown status NCT01505959 Phase 4
13 Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving Continuous Positive Airway Pressure (CPAP) Compliance in Low Cardiovascular Risk Sleep Apnea Patients Unknown status NCT01796769 Phase 4
14 Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome Unknown status NCT00517777 Phase 4
15 Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
16 The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
17 Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing Unknown status NCT00299910 Phase 4 Montelukast
18 Adaptative Servoventilation Compliance in Left Ventricular Dysfunction Patients With Central Sleep Apnea: Benefit of One Month Hypnotic (Zopiclone) Versus Placebo Unknown status NCT02820441 Phase 4 Zopiclone;Placebo
19 Post-tonsillectomy Pain Control in Adults: a Randomized Prospective Study Unknown status NCT02358850 Phase 4 Norco (Hydrocodone and Acetaminophen);Percocet (Oxycodone and Acetaminophen);Dilaudid (hydromorphone);Tylenol (Acetaminophen)
20 Donepezil for Residual Symptoms in CPAP Treated Obstructive Sleepapnea Patients: A Controlled Study Unknown status NCT03299257 Phase 4 donepezil treatment
21 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
22 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
23 Prospective Randomized Equivalence Trial Comparing the Analgesic Efficacy of Ofirmev® Compared to a 1.5 Gram Dose of Oral Acetaminophen for Arthroscopic Rotator Cuff Repair Unknown status NCT01711229 Phase 4 IV acetaminophen;oral acetaminophen
24 Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder Completed NCT00518986 Phase 4 armodafinil;placebo
25 Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (Sodium Oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed NCT00086281 Phase 4 Xyrem (X);Zolpidem (Z);Modafinil (M);Placebo (P)
26 Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome (OSAS) in Children Completed NCT00912171 Phase 4 budesonide (Aircort 50 nasal spray);montelukast (Singulair)
27 Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome Completed NCT00603044 Phase 4 fluticasone furoate
28 Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS). Completed NCT01508754 Phase 4
29 Sleep Apnea-hypopnea Syndrome and Ventricular Arrhythmias in Patients With Systolic Ventricular Dysfunction and Implantable Cardioverter-defibrillator. Incidence and Effect of CPAP Treatment Completed NCT00765713 Phase 4
30 Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension. Completed NCT00409487 Phase 4 Valsartant treatment
31 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
32 Differential Effects of Chronic Treatment of OSAS by CPAP and SOMNOsmart2 on Norepinephrine and Blood Pressure Completed NCT00633711 Phase 4
33 Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
34 Does Nasal Decongestion Improve Obstructive Sleep Apnea ? Completed NCT00630474 Phase 4 xylometazoline
35 Phase 4 Study of the Relationship Between the Oxidative Stress and the Development of Cardiovascular Complications in the Sleep Apnea-hypopnea Syndrome (SAHS). Effect of the Treatment With CPAP Completed NCT00487929 Phase 4
36 Respiratory Impact of Short Life Agents Used in Balanced Anesthesia on Patients Suffering or Suspected of Obstructive Sleep Apnea (OSA) Syndrome Completed NCT02717780 Phase 4 Fentanyl and sevoflurane;Remifentanil and desflurane
37 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP. Completed NCT00360659 Phase 4
38 Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome After Tonsillectomy: A Randomized Controlled Trial Completed NCT02425202 Phase 4 Ketamine
39 Obstructive Sleep Apnea in the Absence of Metabolic Syndrome: Pulse Wave Velocity, Inflammatory and Oxidative Stress Markers Completed NCT01635010 Phase 4
40 Effect Of Nasal CPAP On Glycemic Control In Patients With Poorly Controlled Type 2 Diabetes And Sleep Apnea-Hypopnea Syndrome Completed NCT01801150 Phase 4
41 Cardiovascular Impact of Obstructive Sleep Apnea in Normotensive Patients and the Effects of Continuous Positive Airway Pressure Completed NCT00741520 Phase 4
42 The Effect of Sodium-Restricted Diet and Diuretic in the Severe Sleep Apnea: a Randomized Controlled Trial - DESALT Study Completed NCT01945801 Phase 4 Lasilactone;Placebo
43 Nitrate and Oxidative Stress in Sleep Apnea Syndrome. Effect of Continuous Positive Airway Pressure Completed NCT00547937 Phase 4
44 Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea Completed NCT00729963 Phase 4 Sibutramine
45 Antihypertensive Effect of Continuous Positive Airway Pressure (CPAP) in Resistant Hypertensive Patients With Sleep Apnea: Randomized Clinical Trial Completed NCT00929175 Phase 4
46 Serotonin and the Upper Airway in Obstructive Sleep Apnea Completed NCT00100464 Phase 4 Paroxetine;5HTP
47 The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome Completed NCT01699126 Phase 4 Statin
48 Randomized, Double-blind Study to Compare Safety and Effectiveness of the ProventTM Professional Sleep Apnea Therapy Device to Sham for the Non-invasive Treatment of OSAH Completed NCT00772044 Phase 4
49 Pillar Palatal Implant System Multi-Institutional, Randomized Placebo-Controlled Study for Obstructive Sleep Apnea Completed NCT00307957 Phase 4
50 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo

Search NIH Clinical Center for Apnea, Obstructive Sleep

Cochrane evidence based reviews: sleep apnea, obstructive

Genetic Tests for Apnea, Obstructive Sleep

Genetic tests related to Apnea, Obstructive Sleep:

# Genetic test Affiliating Genes
1 Obstructive Sleep Apnea Syndrome 29

Anatomical Context for Apnea, Obstructive Sleep

MalaCards organs/tissues related to Apnea, Obstructive Sleep:

40
Heart, Testes, Endothelial, Lung, Tongue, Brain, Liver

Publications for Apnea, Obstructive Sleep

Articles related to Apnea, Obstructive Sleep:

(show top 50) (show all 5049)
# Title Authors PMID Year
1
Familial aggregates in obstructive sleep apnea syndrome. 61 56
7781344 1995
2
Atrial flutter associated with obstructive sleep apnea syndrome. A case report. 61 56
7352787 1980
3
APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. 56
17636061 2007
4
Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. 56
16116137 2005
5
APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. 56
15326239 2004
6
Serum amyloid a in obstructive sleep apnea. 56
12952844 2003
7
A whole-genome scan for obstructive sleep apnea and obesity. 56
12506338 2003
8
Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. 56
12003609 2002
9
Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. 56
11401610 2001
10
The genetics of sleep apnea. 56
12531037 2000
11
Familial predisposition to snoring. 56
8153952 1994
12
Is the sleep apnoea/hypopnoea syndrome inherited? 56
8153920 1993
13
Studies in the genetics of obstructive sleep apnea. Familial aggregation of symptoms associated with sleep-related breathing disturbances. 56
1736754 1992
14
Familial 'sleep apnea plus' syndrome: report of a family. 56
3257550 1988
15
Sleeping and breathing. 56
692617 1978
16
Obstructive sleep apnea in family members. 56
211413 1978
17
The sleep apnea syndromes. 56
180875 1976
18
Plasma adiponectin level and sleep structures in children with Prader-Willi syndrome. 54 61
19912511 2010
19
Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. 54 61
18365276 2008
20
Re: Leptin and leptin receptor gene polymorphisms in obstructive sleep apnea syndrome. 54 61
18574304 2008
21
Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. 54 61
18981626 2008
22
Leptin and leptin receptor gene polymorphisms in obstructive sleep apnea syndrome. 54 61
17989154 2008
23
Leptin measurement in urine is a reliable method of monitoring its secretion in patients with obstructive sleep apnea syndrome. 54 61
18204121 2007
24
Frequency of distribution of leptin receptor gene polymorphism in obstructive sleep apnea patients. 54 61
18204169 2007
25
Reduced levels of adiponectin in sleep apnea syndrome. 54 61
17033258 2006
26
[The influence of 3 weeks therapy with continuous positive airway pressure on serum leptin and homocysteine concentration in patients with obstructive sleep apnea syndrome]. 54 61
17175979 2006
27
Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome. 54 61
16088283 2005
28
Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. 54 61
15516536 2005
29
Adiponectin in patients with obstructive sleep apnea syndrome: course and physiological relevance. 54 61
15627868 2004
30
Decreased plasma levels of orexin-A in sleep apnea. 54 61
15627867 2004
31
The association of the severity of obstructive sleep apnea with plasma leptin levels. 54 61
12759266 2003
32
Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. 54 61
10449691 1999
33
In response to "Obstructive sleep apnea syndrome should always be screened in patients complaining of nocturia". World J Urol. 2018. 61
30656495 2020
34
Is there a correlation between obstructive sleep-apnea syndrome severity and prolidase activity as an oxidative stress marker? 61
32031102 2020
35
The effect of obstructive sleep apnea syndrome on serum S100B and NSE levels: a systematic review and meta-analysis of observational studies. 61
32024492 2020
36
Tobacco smoke exposure as a risk factor for obstructive sleep apnoea in children. 61
32034991 2020
37
The impact of obstructive apnea sleep syndrome on chemical function. 61
32034614 2020
38
Intermittent Hypoxia Impairs Trophoblast Cell Viability by Triggering the Endoplasmic Reticulum Stress Pathway. 61
32016801 2020
39
Improving obesity and blood pressure. 61
31649313 2020
40
The relationship between the findings of vestibular evoked myogenic potentials and severity of obstructive sleep apnea syndrome. 61
31542832 2020
41
Obstructive sleep apnea syndrome in adults with down syndrome: Causes and consequences. Is it a "chicken and egg" question? 61
31706958 2020
42
Effect of a Mandibular Advancement Device on the Upper Airway in a Patient With Obstructive Sleep Apnea. 61
31449205 2020
43
Serum amyloid A: A potential biomarker of lung disorders. 61
31708467 2020
44
Evaluation of retinal fiber thickness and visual pathways with optic coherence tomography and pattern visual evoked potential in different clinical stages of obstructive sleep apnea syndrome. 61
31981012 2020
45
Effectiveness of an Intensive Weight-Loss Program for Severe Obstructive Sleep Apnea Syndrome (OSA) in Patients Undergoing CPAP Treatment: A Randomized Controlled Trial. 61
32003737 2020
46
Association between excessive daytime sleepiness, REM phenotype and severity of obstructive sleep apnea. 61
31913307 2020
47
Bedside approach in the diagnosis obstructive sleep apnea using postprandial oximetry testing: A comparative study with polysomnography. 61
31617287 2020
48
Sexual disorders and dyspnoea among women with obstructive sleep apnea. 61
32000113 2020
49
Anti-Allergic and Anti-Inflammatory Effects and Molecular Mechanisms of Thioredoxin on Respiratory System Diseases. 61
31884805 2020
50
Morning Headache as an Obstructive Sleep Apnea-Related Symptom among Sleep Clinic Patients-A Cross-Section Analysis. 61
31963788 2020

Variations for Apnea, Obstructive Sleep

ClinVar genetic disease variations for Apnea, Obstructive Sleep:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SYNE2 NM_182914.2(SYNE2):c.19624G>T (p.Gly6542Trp)SNV Uncertain significance 598975 rs746433383 14:64685197-64685197 14:64218479-64218479
2 RYR1 NM_000540.2(RYR1):c.10097G>T (p.Arg3366Leu)SNV Uncertain significance 598974 rs137932199 19:39009932-39009932 19:38519292-38519292

Expression for Apnea, Obstructive Sleep

Search GEO for disease gene expression data for Apnea, Obstructive Sleep.

Pathways for Apnea, Obstructive Sleep

Pathways related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.96 REN INS IL6 IGF1 AGT ACE
2
Show member pathways
12.7 TNF LEP INS IL6 ADIPOQ
3
Show member pathways
12.58 NOS3 IGF1 HSPA1A GHRL EDN1
4
Show member pathways
12.25 TNF INS IL6 CRP
6
Show member pathways
12.06 TNF IGF1 EDN1 AGT
7
Show member pathways
12.02 INS IGF1 HSPA1A ADIPOQ
8
Show member pathways
12 TNF IL6 IGF1 EDN1 AGT ACE
9
Show member pathways
11.84 TNF NOS3 INS IL6 AGT
10 11.8 NOS3 INS IL6 IGF1 EDN1
11
Show member pathways
11.76 REN LEP INS IGF1 GHRL AGT
12 11.72 TNF NOS3 IL6 EDN1 AGT
13
Show member pathways
11.68 REN NOS3 AGT ACE
14 11.65 TNF IL6 IGF1
15 11.63 TNF LEP ADIPOQ
16 11.6 REN EDN1 AGT ACE
17 11.53 TNF IL6 IGF1 EDN1
18 11.52 TNF IL6 HSPA1A
19 11.48 NOS3 HSPA1A EDN1
20 11.42 INS IL6 IGF1
21 11.38 TNF IL6 IGF1
22 11.29 TNF LEP INS IL6 IGF1 AGT
23
Show member pathways
11.18 LEP EDN1 CRP
24 10.99 LEP INS GHRL
25 10.95 TNF IL6 CRP
26 10.8 TNF LEP IL6 ADIPOQ

GO Terms for Apnea, Obstructive Sleep

Cellular components related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 TNF REN LEP INS IL6 IGF1
2 cell GO:0005623 9.7 NOS3 IL6 HTR2A HCRT GHRL EDN1
3 extracellular region GO:0005576 9.47 TNF REN LEP INS IL6 IGF1
4 caveola GO:0005901 9.43 NOS3 HTR2A FXYD1

Biological processes related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.12 LEP IL6 IGF1 HSPA1A GHRL AHI1
2 positive regulation of cell proliferation GO:0008284 10.04 LEP INS IL6 IGF1 HTR2A EDN1
3 positive regulation of MAPK cascade GO:0043410 9.93 LEP INS IL6 IGF1
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.91 HTR2A HCRT GHRL EDN1 AGT
5 positive regulation of gene expression GO:0010628 9.91 TNF NOS3 INS IL6 IGF1 HSPA1A
6 cellular response to drug GO:0035690 9.88 REN EDN1 ADIPOQ
7 response to glucocorticoid GO:0051384 9.88 TNF IL6 ADIPOQ
8 positive regulation of cold-induced thermogenesis GO:0120162 9.88 LEP HCRT GHRL ADIPOQ
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF INS IL6 HSPA1A AGT
10 positive regulation of MAP kinase activity GO:0043406 9.87 TNF HTR2A EDN1
11 response to nutrient levels GO:0031667 9.87 LEP GHRL ADIPOQ
12 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.87 HTR2A HCRT AGT
13 positive regulation of protein kinase activity GO:0045860 9.87 TNF MMD ADIPOQ
14 negative regulation of fat cell differentiation GO:0045599 9.85 TNF IL6 ADIPOQ
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF EDN1 AGT
16 response to activity GO:0014823 9.85 LEP EDN1 ADIPOQ
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 TNF LEP IL6 IGF1
18 positive regulation of protein tyrosine kinase activity GO:0061098 9.83 GHRL AGT ACE
19 positive regulation of glucose import GO:0046326 9.83 INS IGF1 ADIPOQ
20 acute-phase response GO:0006953 9.83 INS IL6 CRP
21 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 TNF IL6 IGF1 EDN1
22 phosphatidylinositol 3-kinase signaling GO:0014065 9.82 IGF1 HTR2A EDN1
23 blood vessel remodeling GO:0001974 9.81 NOS3 AGT ACE
24 positive regulation of JAK-STAT cascade GO:0046427 9.8 TNF LEP IL6
25 positive regulation of cytokine production GO:0001819 9.79 TNF LEP AGT
26 positive regulation of mitotic nuclear division GO:0045840 9.79 INS IGF1 EDN1
27 positive regulation of interleukin-8 production GO:0032757 9.78 TNF HSPA1A ADIPOQ
28 positive regulation of cardiac muscle hypertrophy GO:0010613 9.77 IGF1 EDN1 AGT
29 positive regulation of insulin receptor signaling pathway GO:0046628 9.75 LEP INS AGT
30 positive regulation of glycolytic process GO:0045821 9.74 INS IGF1 HTR2A
31 regulation of vasoconstriction GO:0019229 9.73 EDN1 AGT ACE
32 positive regulation of cellular protein metabolic process GO:0032270 9.72 INS AGT ADIPOQ
33 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.72 IL6 IGF1 HTR2A AGT ADIPOQ
34 negative regulation of blood vessel diameter GO:0097756 9.71 INS CRP
35 negative regulation of hormone secretion GO:0046888 9.71 EDN1 ADIPOQ
36 adult feeding behavior GO:0008343 9.71 LEP GHRL
37 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.71 IGF1 EDN1
38 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 TNF IGF1 EDN1 AGT
39 neutrophil mediated immunity GO:0002446 9.7 IL6 ACE
40 ovulation from ovarian follicle GO:0001542 9.69 NOS3 LEP
41 bone mineralization involved in bone maturation GO:0035630 9.68 LEP IGF1
42 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.68 NOS3 EDN1
43 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.68 AGT ACE
44 regulation of transmission of nerve impulse GO:0051969 9.67 GHRL AGT
45 renin-angiotensin regulation of aldosterone production GO:0002018 9.66 REN AGT
46 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 TNF LEP INS IGF1 AGT
47 regulation of blood volume by renin-angiotensin GO:0002016 9.64 REN AGT
48 negative regulation of potassium ion transport GO:0043267 9.63 NOS3 HTR2A HCRT
49 artery smooth muscle contraction GO:0014824 9.61 HTR2A EDN1 AGT
50 regulation of renal output by angiotensin GO:0002019 9.6 AGT ACE

Molecular functions related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 TNF IL6 EDN1 ADIPOQ
2 signaling receptor binding GO:0005102 9.55 REN LEP HSPA1A EDN1 ADIPOQ
3 hormone activity GO:0005179 9.17 LEP INS IGF1 GHRL EDN1 AGT
4 insulin-like growth factor receptor binding GO:0005159 9.13 REN INS IGF1

Sources for Apnea, Obstructive Sleep

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....